Masimo SET ® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 ...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that RD SET™ sensors with Masimo Measure-through Motion and Low Perfusion™ SET ® pulse oximetry have received FDA clearance with ...
More than a decade into their partnership, Masimo and GE HealthCare are still finding new ways to combine their respective patient monitoring technologies. In the latest expansion of their ...
Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ Universal Surveillance Monitoring with Masimo SET ® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to ...
Masimo Corp.’s sales pulse has quickened over the past few years. “Pulse oximetry, I think, is going to become a household name over the next decade,” said Joe Kiani, Masimo’s founder and chief ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced Dual SET® Pulse Oximetry for Root®, a highly versatile patient monitoring and connectivity hub. The first application of ...
About a year after beginning its full market launch, Masimo’s W1 smartwatch can now be used as a medical device in the U.S. The wearable device has earned FDA clearance for its medical applications, ...
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient ...
Masimo today announced the results of a prospective study published in the International Journal of Neonatal Screening in which researchers in Marrakesh, Morocco, conducted the first Moroccan study on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback